Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)

Endocrine Tumor Clinical Trial

— eurocrine  

Official title:

Registre Tumeurs Endocrine - Eurocrine

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03410394
• Other study ID #: N° CCTIRS :15.291 Version N°3
• Status: Recruiting
• Start date: January 1, 2015
• Est. completion date: January 1, 2025

Study information

• Verified date: March 2022
• Source: Central Hospital, Nancy, France
• Contact: laurent Brunaud, MD, PhD
• Email: l.brunaud[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.

Description:

The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital

Exclusion Criteria:

• unable to receive clear information

• refusal to sign the consent form

Related Conditions & MeSH terms

• Endocrine Gland Neoplasms
• Endocrine Tumor

Locations

Country	Name	City	State
France	CHU Nancy	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative complications (endocrine surgical procedure)	morbidity rate in percentage (%)	12 months after surgical procedure
Secondary	Postoperative complications severity (endocrine surgical procedure)	Dindo-Clavien classification in percentage (%)	12 months after surgical procedure
Secondary	Postoperative mortality (endocrine surgical procedure)	mortality rate in percentage (%)	12 months after surgical procedure
Secondary	CT imaging before endocrine surgical procedure (Tumor characteristics)	Density in Hounsfield unit (HU)	Baseline
Secondary	CT imaging before endocrine surgical procedure (Coronary artery score)	CAC score in Agatston score unit (HU)	Baseline
Secondary	CT imaging before endocrine surgical procedure (Sarcopenia)	Evaluation of sarcopenia using L3 skeletal muscle index (in cm²/m²)	preoperative period
Secondary	Bone mineral density	dual-energy x-ray absorptiometry (DEXA) (in T-score unit)	Baseline
Secondary	Intraoperative systolic arterial pressure	systolic arterial pressure (in mmHg)	Intraoperative
Secondary	Intraoperative diastolic arterial pressure	diastolic arterial pressure (in mmHg)	Intraoperative
Secondary	Parathormone plasma levels	Parathormone (in pg/mL)	Baseline and up to 12 months after surgical procedure
Secondary	Aldosterone plasma levels	Aldosterone (in pmol/L)	Baseline and up to 12 months after surgical procedure
Secondary	Plasma renin activity	Renin (in µIU/mL)	Baseline and up to 12 months after surgical procedure
Secondary	Plasma free metanephrines	metanephrines (in nmol/L)	Baseline and up to 12 months after surgical procedure
Secondary	PET scanning	standardized uptake values (SUV tumor / SUV liver ratio)	Baseline

External Links

•   EUROCRINE WEB SITE